Literature DB >> 23184615

Defective bile salt biosynthesis and hydroxylation in mice with reduced cytochrome P450 activity.

Cindy Kunne1, Alexandra Acco, Simon Hohenester, Suzanne Duijst, Dirk R de Waart, Alaleh Zamanbin, Ronald P J Oude Elferink.   

Abstract

UNLABELLED: The difference in bile salt (BS) composition between rodents and humans is mainly caused by formation of muricholate in rodents as well as by efficient rehydroxylation of deoxycholic acid. The aim of this study was to characterize bile formation in a mouse model (Hrn mice) with hepatic disruption of the cytochrome p450 (CYP) oxidoreductase gene, encoding the single electron donor for all CYPs. Bile formation was studied after acute BS infusion or after feeding a BS-supplemented diet for 3 weeks. Fecal BS excretion in Hrn mice was severely reduced to 7.6% ± 1.8% of wild-type (WT), confirming strong reduction of (CYP-mediated) BS synthesis. Hrn bile contained 48% ± 18% dihydroxy BS, whereas WT bile contained only 5% ± 1% dihydroxy BS. Upon tauroursodeoxycholate infusion, biliary BS output was equal in WT versus Hrn, indicating that canalicular secretion capacity was normal. In contrast, taurodeoxycholic acid (TDC) infusion led to markedly impaired bile flow and BS output, suggesting onset of cholestasis. Feeding a cholate-supplemented diet (0.1%) resulted in a completely restored bile salt pool in Hrn mice, with 50% ± 9% TDC and 42% ± 10% taurocholic acid in bile, as opposed to 2% ± 1% and 80% ± 3% in WT mice, respectively. Under these conditions, biliary cholesterol secretion was strongly increased in Hrn mice, whereas serum alanine aminotransferase levels were decreased.
CONCLUSION: Hrn mice have strongly impaired bile salt synthesis and (re)hydroxylation capacity and are more susceptible to acute TDC-induced cholestasis. In this mouse model, a more-human BS pool can be instilled by BS feeding, without hepatic damage, which makes Hrn mice an attractive model to study the effects of human BS.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23184615     DOI: 10.1002/hep.26133

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  10 in total

1.  Hepatic cytochrome P450 deficiency in mouse models for intrahepatic cholestasis predispose to bile salt-induced cholestasis.

Authors:  Cindy Kunne; Marijke de Graaff; Suzanne Duijst; Dirk R de Waart; Ronald P J Oude Elferink; Coen C Paulusma
Journal:  Lab Invest       Date:  2014-07-28       Impact factor: 5.662

2.  ATP11C targets basolateral bile salt transporter proteins in mouse central hepatocytes.

Authors:  Dirk R de Waart; Jyoti Naik; Karina S Utsunomiya; Suzanne Duijst; Kam Ho-Mok; A Ruth Bolier; Johan Hiralall; Laura N Bull; Piter J Bosma; Ronald P J Oude Elferink; Coen C Paulusma
Journal:  Hepatology       Date:  2016-04-06       Impact factor: 17.425

3.  Regulation of bile acid metabolism in mouse models with hydrophobic bile acid composition.

Authors:  Akira Honda; Teruo Miyazaki; Junichi Iwamoto; Takeshi Hirayama; Yukio Morishita; Tadakuni Monma; Hajime Ueda; Seiya Mizuno; Fumihiro Sugiyama; Satoru Takahashi; Tadashi Ikegami
Journal:  J Lipid Res       Date:  2019-10-23       Impact factor: 5.922

Review 4.  Animal models to study bile acid metabolism.

Authors:  Jianing Li; Paul A Dawson
Journal:  Biochim Biophys Acta Mol Basis Dis       Date:  2018-05-18       Impact factor: 5.187

Review 5.  Intestinal transport and metabolism of bile acids.

Authors:  Paul A Dawson; Saul J Karpen
Journal:  J Lipid Res       Date:  2014-09-10       Impact factor: 5.922

6.  Simple steatosis sensitizes cholestatic rats to liver injury and dysregulates bile salt synthesis and transport.

Authors:  Daniël A Lionarons; Michal Heger; Rowan F van Golen; Lindy K Alles; Vincent A van der Mark; Jaap J Kloek; Dirk R de Waart; Hendrik A Marsman; Henny Rusch; Joanne Verheij; Ulrich Beuers; Coen C Paulusma; Thomas M van Gulik
Journal:  Sci Rep       Date:  2016-08-18       Impact factor: 4.379

7.  FXR agonism protects against liver injury in a rat model of intestinal failure-associated liver disease.

Authors:  Kiran V K Koelfat; Ruben G J Visschers; Caroline M J M Hodin; D Rudi de Waart; Wim G van Gemert; Jack P M Cleutjens; Marion J Gijbels; Ronit Shiri-Sverdlov; Rajeshwar P Mookerjee; Kaatje Lenaerts; Frank G Schaap; Olde Damink Steven W M
Journal:  J Clin Transl Res       Date:  2017-10-15

8.  Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.

Authors:  Serge J Zweers; Elisabeth M de Vries; Martin Lenicek; Dagmar Tolenaars; D Rudi de Waart; Kiran V K Koelfat; Albert K Groen; Steven W M Olde Damink; Ulrich Beuers; Cyriel Ponsioen; Peter L M Jansen; Frank G Schaap
Journal:  Hepatol Int       Date:  2016-09-30       Impact factor: 6.047

9.  Glycochenodeoxycholate Promotes Liver Fibrosis in Mice with Hepatocellular Cholestasis.

Authors:  Simon Hohenester; Veronika Kanitz; Andreas E Kremer; Coen C Paulusma; Ralf Wimmer; Helen Kuehn; Gerald Denk; David Horst; Ronald Oude Elferink; Ulrich Beuers
Journal:  Cells       Date:  2020-01-23       Impact factor: 6.600

10.  Exclusive enteral nutrition mediates gut microbial and metabolic changes that are associated with remission in children with Crohn's disease.

Authors:  Kay Diederen; Jia V Li; Gillian E Donachie; Tim G de Meij; Dirk R de Waart; Theodorus B M Hakvoort; Angelika Kindermann; Josef Wagner; Victoria Auyeung; Anje A Te Velde; Sigrid E M Heinsbroek; Marc A Benninga; James Kinross; Alan W Walker; Wouter J de Jonge; Jurgen Seppen
Journal:  Sci Rep       Date:  2020-11-03       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.